This review highlights the need for enhancements in doxorubicin chemistry, delivery, and toxicity management to prolong its clinical utility against cancer.
No takes yet. Share an insight, caveat, or question.
Should not yet alter doxorubicin use in oncology; leaves open targeted chemistry and delivery enhancements for prospective trials.
Tacar et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: